Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Status:
Completed
Trial end date:
2018-04-23
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset
counts during the first year of treatment in subjects with relapsing-remitting multiple
sclerosis (RRMS). A secondary objective is to evaluate the pharmacodynamic effect on absolute
lymphocyte counts (ALCs) and immunoglobulins (Igs) during the first year of treatment.